| GlaxoSmithKline AG - Fluarix Tetra 15 µg / 0.5 ml, Injektionssuspension | | 62961 | | 06 | | Fluarix Tetra 15 µg / 0.5 ml | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 08.08.2019 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: reassortant virus IVR-190 derived from A/Brisbane/02/2018) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: reassortant virus NYMC X-327 derived from A/Kansas/14/0217) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant virus B/Maryland/15/2016 NYMC BX-69A (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013 (Yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | | | | | | | Wirkstoffe | Stärke |
|---|
| | 15 µg | | | 15 µg | | | 15 µg |
| | | | Hilfsstoffe | Stärke | Zusätzliche Information |
|---|
| | | | | Dinatrii Phosphas Dodecahydricus | | | | Formaldehydum | 5 µg | | | | | | | | 15 µg | | | | | | | Kalii Chloridum | | | | Kalii Dihydrogenophosphas | | | | Magnesii Chloridum Hexahydricum | | | | Natrii Chloridum | | | | | 65 µg | | | | | | | | 0.05 µg | residui | | Polysorbatum 80 | | |
|
| | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| Es wurden keine Einträge gefunden. |
|
|
